Deep venous thrombosis

Contemporary Urology

Volumn 18, Issue 5, 2006, Pages 48-54

  Copeland, Duan C ^a   Gretzer, Matthew B ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845736857     PISSN: 10422250     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Zamorski MA, Opdycke RA. Advances in the prevention, diagnosis and treatment of deep venous thrombosis. Am Fam Physician. 1993;47(2):457-469.
2. Kibel AS, Loughlin KR. Pathogenesis and prophylaxis of postoperative thromboembolic disease in urological pelvic surgery. J Urol. 1995;153(6):1763-1774.
3. Virchow R. Cellular pathology. As based upon physiological and pathological histology. Lecture XVI-Atheromatous affection of arteries. 1858. Nutr Rev. 1989;47(1):23-25.
4. Donati MB. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost. 1995;74(1):278-281.
5. Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am. 1996;10(2):499-530.
6. Thompson CM, Rodgers RL. Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the inddence of thromboembolism. Am J Med Sci. 1952;223(5):469-478.
7. Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol. 1996;14(10):2731-2737.
8. Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost. 1996;75(2):251-253.
9. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembblism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18(17):3078-3083.
10. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med. 1996;335(2):108-114.
11. Safir MH, McAninch JW. Diagnosis and management of trauma to the kidney. Curr Opin Urol. 1999;9(3):227-231.
12. Santucci RA, McAninch JW. Diagnosis and management of renal trauma: past, present and future. J Am Coll Surg. 2000;191(4):443-451.
13. Rogers FB. Venous thromboembolism in trauma patients: a review. Surgery. 2001;130(1):1-12.
14. Peck MD, Boileau MA, Grube BJ, et al. The management of burns to the perineum and genitals. J Burn Care Rehab. 1990;1(11):54-56.
15. Harrington DT, Mozingo DW, Cancio L, et al. Thermally injured patients are at significant risk for thromboembolic complications. J Trauma. 2001;50(3):495-499.
16. Stein PD. Pulmonary Embolism. Baltimore, Md: Williams & Wilkins; 1996.
17. Anand SS, Wells PS, Hunt D, et al. Does this patient have deep vein thrombosis? JAMA. 1998;279(14):1094-1099.
18. Wells PS, Hirsh J, Andersen DR, et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet. 1995;345(8961):1326-1330.
19. Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997;350:1796.
20. Agu O, Hamilton G, Baker D. Graduated compression stockings in the prevention of venous thromboembolism. Br J Surg. 1999;86(8):992-1004.
21. Comerota AJ, Chouhan V, Harada RN, et al. The fibrinorytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg. 1997;226(3):306-313.
22. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled clinical trial. Lancet. 1960;18(1):1309-1312.
23. Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost. 1988;60(3):457-462.
24. Ofosu FA, Hirsh J, Esmon CT, et al. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa. Biochem J. 1989;257(1):143-150.
25. Simon TL, Hyers TM, Gaston JP, et al. Heparin pharmacokinetics: increased requirements in pulmonary embolism. Br J Hematol. 1978;39(1):111-120.
26. Crowther MA, Ginsberg J, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med. 1999;159(1):46-48.
27. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114(5):445S-695S.
28. Andrassy K, Eschenfelder V. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res. 1996;81(2):S29-S38.
29. Lindahl AK, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res. 1991;64(2):155-168.
30. Weitz JI. New anticoagulants for treatment of venous thromboembolism. Circulation. 2004;110(9 suppl 1):119-126.
31. Turpie AG, Eriksson BI, Bauer KA, et al. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. Chest. 2003;124(6 suppl):371S-378S.
32. Bergqvist D, Bergentz SE, Bommyr S, et al. Deep vein thrombosis after renal transplantation: a prospective analysis of frequency and risk factors. Eur Surg Res. 1985;17(2):69-74.
33. Van Arsdalen KN, Barnes RW, Clarke G, et al. Deep vein thrombosis and prostatectomy. Urology. 1983;21(5):461-463.
34. Allen NH, Jenkins JD, Smart CJ. Surgical haemorrhage in patients given subcutaneous heparin as prophylaxis against thromboembolism. Br Med J. 1978;1(6123):1326.
35. Sleight MW. The effect of prophylactic subcutaneous heparin on blood loss during and after transurethral prostatectomy. Br J Urol. 1982;54(2):164-165.
36. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):338S-400S.
37. Kibel AS, Creager MA, Goldhaber SZ, et al. Late venous thromboembolic disease after radical prostatectomy: effect of risk factors, warfarin and early discharge. J Urol. 1997;158(6):2211-2215.